Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Riociguat Formulations
NCT02159313Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of riociguat in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) (4 arms), sponsored by Bayer. Primary endpoints: Area under the plasma concentration time curve and Maximal concentration. Started Jun 2014; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT02159313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02159313.